Home › Compare › ENTFW vs ABBV

ENTFW vs ABBV: Dividend Comparison 2026

ENTFW yields 111111.11% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ENTFW wins by $1.3838190899465547e+27M in total portfolio value
10 years
ENTFW
ENTFW
● Live price
111111.11%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.3838190899465547e+27M
Annual income
$1,381,373,456,343,941,000,000,000,000,000,000.00
Full ENTFW calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ENTFW vs ABBV

📍 ENTFW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodENTFWABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ENTFW + ABBV cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ENTFW pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ENTFW
Annual income on $10K today (after 15% tax)
$9,444,444.44/yr
After 10yr DRIP, annual income (after tax)
$1,174,167,437,892,349,800,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ENTFW beats the other by $1,174,167,437,892,349,800,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ENTFW + ABBV for your $10,000?

ENTFW: 50%ABBV: 50%
100% ABBV50/50100% ENTFW
Portfolio after 10yr
$6.919095449732774e+26M
Annual income
$690,686,728,171,970,500,000,000,000,000,000.00/yr
Blended yield
99.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ENTFW
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ENTFW buys
0
ABBV buys
0
No recent congressional trades found for ENTFW or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricENTFWABBV
Forward yield111111.11% ✓3.06%
Annual dividend / share$2.00$6.65 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6% ✓
Portfolio after 10y$1.3838190899465547e+27M$102.3K ✓
Annual income after 10y$1,381,373,456,343,941,000,000,000,000,000,000.00 ✓$24,771.77
Total dividends collected$1.383658847866035e+27M$61.0K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ENTFW vs ABBV ($10,000, DRIP)

YearENTFW PortfolioENTFW Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,121,811$11,111,111.11$11,550$430.00+$11.11M → ENTFW
2$11,561,029,218$11,549,128,879.66$13,472$627.96+$11561.02M → ENTFW
3$11,232,204,364,934$11,219,834,063,671.13$15,906$926.08+$11232204.35M → ENTFW
4$10,199,601,320,781,262$10,187,582,862,110,782.00$19,071$1,382.55+$10199601320.76M → ENTFW
5$8,656,721,364,988,387,000$8,645,807,791,575,153,000.00$23,302$2,095.81+$8656721364988.36M → ENTFW
6$6,867,176,795,058,000,000,000$6,857,914,103,197,462,000,000.00$29,150$3,237.93+$6867176795058000.00M → ENTFW
7$5,091,669,942,459,710,000,000,000$5,084,322,063,288,997,000,000,000.00$37,536$5,121.41+$5091669942459709440.00M → ENTFW
8$3,528,599,356,203,225,300,000,000,000$3,523,151,269,364,793,600,000,000,000.00$50,079$8,338.38+$3.5285993562032256e+21M → ENTFW
9$2,285,638,880,947,370,600,000,000,000,000$2,281,863,279,636,233,000,000,000,000,000.00$69,753$14,065.80+$2.2856388809473705e+24M → ENTFW
10$1,383,819,089,946,554,900,000,000,000,000,000$1,381,373,456,343,941,000,000,000,000,000,000.00$102,337$24,771.77+$1.3838190899465547e+27M → ENTFW

ENTFW vs ABBV: Complete Analysis 2026

ENTFW — Stock

Enterprise 4.0 Technology Acquisition Corp. was incorporated in 2021 and is based in Burlingame, California.

Full ENTFW Calculator →

ABBV — Healthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ENTFW vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ENTFW vs SCHDENTFW vs JEPIENTFW vs OENTFW vs KOENTFW vs MAINENTFW vs JNJENTFW vs MRKENTFW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.